Cadrenal Therapeutics, Inc. (CVKD) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cadrenal Therapeutics, Inc. has appointed Jeffrey Cole as their new Chief Operating Officer, solidifying the decision with a comprehensive employment agreement. Cole, an industry veteran with over 25 years of experience, has a history of significant roles in pharmaceuticals and consulting. His compensation includes a $405,000 base salary, potential for a 40% bonus, and robust severance and equity vesting terms. His appointment, which brings a wealth of knowledge and expertise to the company, was publicly announced on February 8, 2024.
For further insights into CVKD stock, check out TipRanks’ Stock Analysis page.